Author

P. Shinn

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 4 Biochemistry· 3 Microbiology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 9 Research Focus:drug response / drug discovery· 8 Assay:proteomics· 2 Research Focus:benchmarking· 1 Research Focus:database / resource· 1 Research Focus:host-pathogen & immune response· 1 Organism:virus· 1

Frequent Co-Authors

M. Shen· 7 shared W. Zheng· 7 shared A. Simeonov· 6 shared C. Klumpp-Thomas· 6 shared C. Z. Chen· 6 shared H. Guo· 6 shared Z. Itkin· 6 shared M. Xu· 5 shared

Activity by Year

2020-2022 · peak 7/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

7 shared papersBiochemistry

M. Shen

Mutual co-authors in cluster

Author profile →

9 papers

Recent·Most cited

Quantitative bioactivity signatures of dietary supplements and natural products

A. Yasgar, D. Bougie, C. McKnight, M. Miller, T. Peryea, M. Xia, P. Shah, X. Xu, P. Shinn, M. Itkin, C. Lynch, A. V. Zakharov, R. Eastman, J. Kouznetsova, D. Ngan, , A. Simeonov

The paper screens dietary supplements and natural products for bioactivity using in vitro assays and predicts their mechanisms of action by comparing activity profiles with approved drugs.

bioRxiv · Sep 14, 2022Pharmacology & Toxicology

A Suite of TMPRSS2 Assays for Screening Drug Repurposing Candidates as Potential Treatments of COVID-19

J. H. Shrimp, J. Janiszewski, C. Z. Chen, M. Xu, K. M. Wilson, S. C. Kales, P. E. Sanderson, P. Shinn, Z. Itkin, H. Guo, M. Shen, C. Klumpp-Thomas, S. G. Michael, W. Zheng, A. Simeonov, M. D. Hall

The paper develops and validates a series of assays to identify TMPRSS2 inhibitors as potential COVID-19 treatments, identifying six compounds with varying clinical statuses.

bioRxiv · Feb 4, 2022Biochemistry

Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2

C. Z. Chen, P. Shinn, Z. Itkin, R. Eastman, R. Bostwick, L. Rasmussen, R. Huang, M. Shen, X. Hu, K. M. Wilson, B. Brooks, H. Guo, T. Zhao, C. Klumpp-Thomas, A. Simeonov, , W. Zheng

The paper identifies 319 compounds with anti-SARS-CoV-2 activities through a high-throughput screen, including 91 approved drugs and 49 investigational drugs, with 230 compounds previously unreported.

bioRxiv · Aug 18, 2020Microbiology

Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-throughput Screening

W. Zhu, M. Xu, C. Z. Chen, H. Guo, M. Shen, X. Hu, P. Shinn, C. Klumpp-Thomas, S. G. Michael, W. Zheng

This study identifies 23 SARS-CoV-2 3CLpro inhibitors through high-throughput screening, with several showing potent activity against viral infection.

bioRxiv · Jul 17, 2020Pharmacology & Toxicology

Identifying SARS-CoV-2 entry inhibitors through drug repurposing screens of SARS- S and MERS-S pseudotyped particles

C. Z. Chen, M. Xu, M. Pradhan, K. Gorshkov, J. Petersen, M. R. Straus, W. Zhu, P. Shinn, H. Guo, M. Shen, C. Klumpp-Thomas, S. G. Michael, J. Zimmerberg, W. Zheng, G. R. Whittaker

This paper identifies six broad-spectrum inhibitors of SARS-CoV-2 and MERS-CoV spike-mediated cell entry through drug repurposing screens using pseudotyped particles.

bioRxiv · Jul 10, 2020Pharmacology & Toxicology

Discovery of Synergistic and Antagonistic Drug Combinations against SARS-CoV-2 In Vitro

T. Bobrowski, L. Chen, R. T. Eastman, Z. Itkin, P. Shinn, C. Chen, H. Guo, W. Zheng, S. Michael, A. Simeonov, M. Hall, A. V. Zakharov, E. N. Muratov

This study identifies synergistic and antagonistic drug combinations against SARS-CoV-2 in vitro using in silico prioritization and experimental testing.

bioRxiv · Jun 29, 2020Microbiology

Targeting ACE2-RBD interaction as a platform for COVID19 therapeutics: Development and drug repurposing screen of an AlphaLISA proximity assay

Q. M. Hanson, K. M. Wilson, M. Shen, Z. Itkin, R. T. Eastman, P. Shinn, M. D. Hall

The paper develops an AlphaLISA assay to measure SARS-CoV-2 spike RBD-ACE2 binding and identifies 25 drug candidates that disrupt this interaction.

bioRxiv · Jun 16, 2020Biochemistry

Real-time sharing of drug screening data on the NCATS OpenData Portal accelerates translational research

K. R. Brimacombe, P. C. Scully, T. Zhao, R. T. Eastman, X. Hu, K. Wang, M. Backus, B. Baljinnyam, C. Z. Chen, L. Chen, Y. Cheng, D. P. Davis, K. Duerr, T. Eicher, A. Friedman, , M. D. Hall

This paper describes the NCATS OpenData Portal, a platform for real-time sharing of drug screening data that accelerates translational research by enabling immediate access to large-scale datasets.

bioRxiv · Jun 4, 2020 · PreprintBiochemistry

The SARS-CoV-2 cytopathic effect is blocked with autophagy modulators

K. Gorshkov, C. Z. Chen, R. Bostwick, L. Rasmussen, M. Xu, M. Pradhan, B. N. Tran, W. Zhu, K. Shamim, W. Huang, X. Hu, M. Shen, C. Klumpp-Thomas, Z. Itkin, P. Shinn, , W. Zheng

The paper identifies six autophagy modulators that block SARS-CoV-2 cytopathic effects in Vero-E6 cells with EC50 values between 2.0 and 13 µM.

bioRxiv · May 16, 2020Pharmacology & Toxicology